Table 3.
Indeterminate Cytology Group Analysis by Mutational Testing
| Final histological diagnosis | ||||
|---|---|---|---|---|
| n | 125 | Malignant | Adenoma | Benign |
| No mutational testing, n (% of total indeterminate) | 52 | 25 (44%) | 19 (33%) | 8 (14%) |
| Mutation DNA insufficient, n | 5 | 0 | 0 | 5 |
| Mutational testing, n (% of total indeterminate) | 68 | 27 (41%)a | 18 (26%) | 23 (33%) |
| Mutation positive, n (% of mutation tested histological category) | 24/27 (89%)b,c | 8/18 (44%)d | 6/23 (26%) | |
| Seven-gene mutational test | 23 | 6 | 7 | 10 |
| ThyroSeq® | 45 | 17 | 11 | 17 |
Breakdown of the molecular testing method, if used, in the 125 indeterminate cytology nodules as presented in area in bold in Table 2.
a
p = 0.74 vs. the malignant group that did not get molecular testing.
b
p < 0.0001 malignant vs. (adenoma + benign).
c
p = 0.001 vs. adenoma in the molecular tested groups.
d
p = 0.21 adenoma vs. benign in the molecular tested group.